Main
disability, RRMS, PMS
MULTIPLE SCLEROSIS (MS), PMS
Despite the development of several effective treatments that revolutionized the natural history of multiple sclerosis (MS), their advantages are mainly achieved for patients with relapsing-remitting MS (RRMS), while effective therapies for progressive MS (PMS) still represent an unmet need. In PMS, therapeutic mechanisms of action should combine neuroprotection, immunomodulation and regeneration to hamper irreversible disability progression. Most of the ongoing clinical trials for PMS are assessing repurposed drugs with unsatisfactory results due to lack of tailored targets